Bruker reported Q4-25 revenues of $977.2 million, which was flat year-over-year, and GAAP diluted EPS of $0.10. For the full year 2025, revenues were $3.44 billion, up ~2% year-over-year, with a GAAP diluted loss per share of $(0.15). The company initiated FY26 guidance with expected revenue growth of 4% to 5% and non-GAAP EPS growth of 15% to 17%.

Bruker reported a modest decline in revenue and a GAAP net loss for Q3 2025, driven by earlier market weakness and impairment charges, though non-GAAP earnings exceeded expectations.

In Q2 2025, Bruker posted revenue of $797.4 million and flat GAAP EPS, with pressures from U.S. academic and biopharma markets. The company launched a major cost-reduction plan aiming for a stronger FY2026.

Bruker delivered an 11.0% increase in revenue in Q1 2025, supported by acquisitions and moderate organic growth. Despite strong execution, the company reported a sharp decline in GAAP net income and EPS due to integration costs from 2024 acquisitions. Operating margin expanded on a non-GAAP basis thanks to proactive cost management. The company revised its FY2025 guidance downward due to academic market weakness and tariff impacts.

Bruker reported strong revenue growth of 14.6% YoY in Q4 2024, reaching $979.6M, primarily driven by acquisitions (+11.9%). However, net income dropped significantly (-93.3% YoY) due to higher expenses and acquisition-related costs. Adjusted EPS increased by 8.6% to $0.76.

Bruker reported Q3 2024 revenues of $864.4 million, a 16.4% increase year-over-year. GAAP diluted EPS was $0.27, and non-GAAP diluted EPS was $0.60. The company updated its FY2024 guidance, expecting revenues of $3.34 to $3.37 billion and non-GAAP EPS of $2.36 to $2.41.

Bruker reported strong Q2 2024 results with revenues of $800.7 million, up 17.4% year-over-year, and organic revenue growth of 7.4%. The company's non-GAAP EPS increased by 4.0% to $0.52. Bruker has increased its full-year revenue guidance to $3.38-$3.44 billion, which now includes the NanoString business.

Bruker reported a 5.3% year-over-year increase in revenue for Q1 2024, reaching $721.7 million. Organic revenue grew by 1.6%. The company updated its FY 2024 guidance, projecting revenue between $3.29 and $3.35 billion and non-GAAP EPS of $2.79 to $2.84.

Bruker reported Q4 2023 revenues of $854.5 million, a 20.6% increase year-over-year, with organic revenue up by 15.9%. GAAP EPS was $1.41, including a gain from the PhenomeX acquisition, while non-GAAP EPS was $0.70, a 5.4% decrease year-over-year. The company's full-year revenue reached $2.96 billion, with a 17.1% increase year-over-year and organic revenue growth of 14.5%.

Bruker reported Q3 2023 revenues of $742.8 million, a 16.3% increase year-over-year, with organic revenue up 10.9%. GAAP EPS was $0.60, and non-GAAP EPS was $0.74, up 12.1% year-over-year. The company increased its FY 2023 revenue guidance to $2.88-$2.91 billion, implying a reported revenue growth of 14%-15% year-over-year.

Bruker reported a strong second quarter with a 15.9% increase in revenues to $681.9 million and a GAAP EPS of $0.39. The company has increased its FY 2023 revenue guidance to $2.85-$2.90 billion.

Bruker Corporation reported a strong start to 2023, with Q1 revenues reaching $685.3 million, a 15.2% increase year-over-year. Organic revenue grew by 17.6%. The company raised its full-year guidance for revenue to $2.83-$2.88 billion and non-GAAP EPS to $2.55-$2.60.

Bruker's Q4 2022 results showed revenue growth, driven by strong organic performance. The company reported an increase in both GAAP and non-GAAP EPS, with non-GAAP EPS growing significantly. The company is guiding for continued revenue and EPS growth in FY 2023.

Bruker reported a 4.9% year-over-year increase in revenue, with organic revenue growth of 12.7%. The GAAP operating margin was 20.6%, while the non-GAAP operating margin reached 22.4%. GAAP EPS was $0.59, and non-GAAP EPS was $0.66, a 4.8% increase year-over-year. Due to strong year-to-date performance and a high backlog, the company is raising its FY 2022 guidance for organic revenue growth and non-GAAP operating margin expansion.

Bruker reported a 3.1% year-over-year increase in revenue for Q2 2022, with organic revenue growth of 8.8%. GAAP EPS was $0.33, and non-GAAP EPS was $0.45, a 2.3% increase year-over-year. The company is maintaining its FY 2022 guidance for high single-digit organic revenue growth, non-GAAP operating profit margin expansion, and non-GAAP EPS increase.

Bruker Corporation reported a 7.3% increase in revenue for Q1 2022, reaching $595.0 million, with organic revenue growth of 10.5%. The company's GAAP EPS was $0.41, and non-GAAP EPS was $0.49, a rise of 11.4% year-over-year. Due to strong demand, Bruker is raising its fiscal year 2022 organic revenue outlook.

Bruker reported Q4 2021 revenues of $683.5 million, an 8.9% increase year-over-year, with organic revenue growth of 11.4%. GAAP EPS was $0.50, and non-GAAP EPS was $0.59, up $0.01 year-over-year. The company anticipates solid organic revenue and non-GAAP EPS growth in FY 2022.

Bruker reported a strong third quarter in 2021, with revenues up 19.1% year-over-year to $608.9 million. GAAP EPS increased by 63% to $0.57, and non-GAAP EPS rose by 50% to $0.63. The company is raising its full-year 2021 guidance due to strong demand.

Bruker Corporation reported a strong second quarter in 2021, with a revenue increase of 34.4% compared to the second quarter of 2020. GAAP EPS was $0.38 and non-GAAP EPS was $0.44. The company is raising its fiscal year 2021 guidance for revenue growth, non-GAAP operating margin expansion and non-GAAP EPS.

Bruker Corporation reported a 30.8% increase in revenue for Q1 2021, with organic revenue growth of 23.8%. GAAP EPS was $0.37, and non-GAAP EPS was $0.44. The company is raising its fiscal year 2021 outlook due to strong demand.

Bruker Corporation reported a 4.6% increase in revenue for Q4 2020, reaching $627.5 million. GAAP EPS was $0.45, while non-GAAP EPS increased by 9.4% to $0.58. The company experienced growth in non-GAAP operating income and margin, driven by strong gross margin performance and expense control.

Bruker's Q3 2020 revenues were $511.4 million, a 1.9% decrease compared to Q3 2019. GAAP operating income was $81.2 million, with a margin of 15.9%. Non-GAAP operating income was $94.9 million, with a margin of 18.6%. GAAP EPS was $0.35, and non-GAAP EPS was $0.42. The declines were primarily due to softer instrument and superconductor demand amid the pandemic, partially offset by cost control measures.

Bruker's Q2 2020 revenues were $424.6 million, a 13.4% decrease compared to Q2 2019. GAAP EPS was $0.16, and non-GAAP EPS was $0.21. The company mitigated the negative impact on profitability through cost control measures.

Bruker reported a revenue decline of 8.1% year-over-year, with an organic revenue decline of 7.9%. GAAP EPS decreased to $0.07 from $0.20 in Q1 2019, and non-GAAP EPS decreased to $0.14 from $0.28 in Q1 2019. The company expects COVID-19 disruptions to negatively affect Q2 2020 financial results.

Bruker Corporation reported an 8.4% increase in revenue for Q4 2019, reaching $599.9 million. GAAP operating income was $117.7 million, with a margin of 19.6%. However, GAAP EPS decreased to $0.44, and non-GAAP EPS decreased to $0.53, driven by a higher effective tax rate.